FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068045221> ?p ?o ?g. }

• W2068045221 endingPage "192" @default.
• W2068045221 startingPage "184" @default.
• W2068045221 abstract "Inflammatory bowel disease (IBD) is a common condition in dogs, and a dysregulated innate immunity is believed to play a major role in its pathogenesis. S100A12 is an endogenous damage-associated molecular pattern molecule, which is involved in phagocyte activation and is increased in serum/fecal samples from dogs with IBD. S100A12 binds to the receptor of advanced glycation end products (RAGE), a pattern-recognition receptor, and results of studies in human patients with IBD and other conditions suggest a role of RAGE in chronic inflammation. Soluble RAGE (sRAGE), a decoy receptor for inflammatory proteins (e.g., S100A12) that appears to function as an anti-inflammatory molecule, was shown to be decreased in human IBD patients. This study aimed to evaluate serum sRAGE and serum/fecal S100A12 concentrations in dogs with IBD. Serum and fecal samples were collected from 20 dogs with IBD before and after initiation of medical treatment and from 15 healthy control dogs. Serum sRAGE and serum and fecal S100A12 concentrations were measured by ELISA, and were compared between dogs with IBD and healthy controls, and between dogs with a positive outcome (i.e., clinical remission, n = 13) and those that were euthanized (n = 6). The relationship of serum sRAGE concentrations with clinical disease activity (using the CIBDAI scoring system), serum and fecal S100A12 concentrations, and histologic disease severity (using a 4-point semi-quantitative grading system) was tested. Serum sRAGE concentrations were significantly lower in dogs with IBD than in healthy controls (p = 0.0003), but were not correlated with the severity of histologic lesions (p = 0.4241), the CIBDAI score before (p = 0.0967) or after treatment (p = 0.1067), the serum S100A12 concentration before (p = 0.9214) and after treatment (p = 0.4411), or with the individual outcome (p = 0.4066). Clinical remission and the change in serum sRAGE concentration after treatment were not significantly associated (p = 0.5727); however, serum sRAGE concentrations increased only in IBD dogs with complete clinical remission. Also, dogs that were euthanized had significantly higher fecal S100A12 concentrations than dogs that were alive at the end of the study (p = 0.0124). This study showed that serum sRAGE concentrations are decreased in dogs diagnosed with IBD compared to healthy dogs, suggesting that sRAGE/RAGE may be involved in the pathogenesis of canine IBD. Lack of correlation between sRAGE and S100A12 concentrations is consistent with sRAGE functioning as a non-specific decoy receptor. Further studies need to evaluate the gastrointestinal mucosal expression of RAGE in healthy and diseased dogs, and also the formation of S100A12-RAGE complexes." @default.
• W2068045221 created "2016-06-24" @default.
• W2068045221 creator A5001684704 @default.
• W2068045221 creator A5009711546 @default.
• W2068045221 creator A5017199731 @default.
• W2068045221 creator A5018799234 @default.
• W2068045221 creator A5036496208 @default.
• W2068045221 creator A5073922918 @default.
• W2068045221 date "2014-10-01" @default.
• W2068045221 modified "2023-10-14" @default.
• W2068045221 title "Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease" @default.
• W2068045221 cites W1520402836 @default.
• W2068045221 cites W1979731419 @default.
• W2068045221 cites W1981571079 @default.
• W2068045221 cites W1984830754 @default.
• W2068045221 cites W1995581789 @default.
• W2068045221 cites W2002107602 @default.
• W2068045221 cites W2008011385 @default.
• W2068045221 cites W2018620079 @default.
• W2068045221 cites W2027590052 @default.
• W2068045221 cites W2048604656 @default.
• W2068045221 cites W2069682711 @default.
• W2068045221 cites W2070636077 @default.
• W2068045221 cites W2071675524 @default.
• W2068045221 cites W2072447266 @default.
• W2068045221 cites W2074280408 @default.
• W2068045221 cites W2084751368 @default.
• W2068045221 cites W2104938297 @default.
• W2068045221 cites W2109334664 @default.
• W2068045221 cites W2112132580 @default.
• W2068045221 cites W2134643141 @default.
• W2068045221 cites W2136935685 @default.
• W2068045221 cites W2161528116 @default.
• W2068045221 cites W2316574236 @default.
• W2068045221 cites W4241628985 @default.
• W2068045221 cites W4245277907 @default.
• W2068045221 doi "https://doi.org/10.1016/j.vetimm.2014.08.003" @default.
• W2068045221 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25183017" @default.
• W2068045221 hasPublicationYear "2014" @default.
• W2068045221 type Work @default.
• W2068045221 sameAs 2068045221 @default.
• W2068045221 citedByCount "17" @default.
• W2068045221 countsByYear W20680452212015 @default.
• W2068045221 countsByYear W20680452212016 @default.
• W2068045221 countsByYear W20680452212017 @default.
• W2068045221 countsByYear W20680452212018 @default.
• W2068045221 countsByYear W20680452212019 @default.
• W2068045221 countsByYear W20680452212020 @default.
• W2068045221 countsByYear W20680452212021 @default.
• W2068045221 countsByYear W20680452212022 @default.
• W2068045221 crossrefType "journal-article" @default.
• W2068045221 hasAuthorship W2068045221A5001684704 @default.
• W2068045221 hasAuthorship W2068045221A5009711546 @default.
• W2068045221 hasAuthorship W2068045221A5017199731 @default.
• W2068045221 hasAuthorship W2068045221A5018799234 @default.
• W2068045221 hasAuthorship W2068045221A5036496208 @default.
• W2068045221 hasAuthorship W2068045221A5073922918 @default.
• W2068045221 hasConcept C126322002 @default.
• W2068045221 hasConcept C147990577 @default.
• W2068045221 hasConcept C169760540 @default.
• W2068045221 hasConcept C170493617 @default.
• W2068045221 hasConcept C203014093 @default.
• W2068045221 hasConcept C2776914184 @default.
• W2068045221 hasConcept C2778260677 @default.
• W2068045221 hasConcept C2778857457 @default.
• W2068045221 hasConcept C2779134260 @default.
• W2068045221 hasConcept C2779179475 @default.
• W2068045221 hasConcept C2780479503 @default.
• W2068045221 hasConcept C2780942790 @default.
• W2068045221 hasConcept C61716771 @default.
• W2068045221 hasConcept C71924100 @default.
• W2068045221 hasConcept C86803240 @default.
• W2068045221 hasConcept C89423630 @default.
• W2068045221 hasConceptScore W2068045221C126322002 @default.
• W2068045221 hasConceptScore W2068045221C147990577 @default.
• W2068045221 hasConceptScore W2068045221C169760540 @default.
• W2068045221 hasConceptScore W2068045221C170493617 @default.
• W2068045221 hasConceptScore W2068045221C203014093 @default.
• W2068045221 hasConceptScore W2068045221C2776914184 @default.
• W2068045221 hasConceptScore W2068045221C2778260677 @default.
• W2068045221 hasConceptScore W2068045221C2778857457 @default.
• W2068045221 hasConceptScore W2068045221C2779134260 @default.
• W2068045221 hasConceptScore W2068045221C2779179475 @default.
• W2068045221 hasConceptScore W2068045221C2780479503 @default.
• W2068045221 hasConceptScore W2068045221C2780942790 @default.
• W2068045221 hasConceptScore W2068045221C61716771 @default.
• W2068045221 hasConceptScore W2068045221C71924100 @default.
• W2068045221 hasConceptScore W2068045221C86803240 @default.
• W2068045221 hasConceptScore W2068045221C89423630 @default.
• W2068045221 hasIssue "3-4" @default.
• W2068045221 hasLocation W20680452211 @default.
• W2068045221 hasLocation W20680452212 @default.
• W2068045221 hasOpenAccess W2068045221 @default.
• W2068045221 hasPrimaryLocation W20680452211 @default.
• W2068045221 hasRelatedWork W1995801352 @default.
• W2068045221 hasRelatedWork W2027819189 @default.
• W2068045221 hasRelatedWork W2029536434 @default.
• W2068045221 hasRelatedWork W2078213156 @default.

• next